Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.

Li L, Schaid DJ, Fridley BL, Kalari KR, Jenkins GD, Abo RP, Batzler A, Moon I, Pelleymounter L, Eckloff BW, Wieben ED, Sun Z, Yang P, Wang L.

Pharmacogenet Genomics. 2012 Feb;22(2):105-16. doi: 10.1097/FPC.0b013e32834dd7e2.

2.

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ.

J Thorac Oncol. 2012 Jun;7(6):973-81. doi: 10.1097/JTO.0b013e31824fe98c.

3.

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.

Mlak R, Krawczyk P, Ciesielka M, Kozioł P, Homa I, Powrózek T, Prendecka M, Milanowski J, Małecka-Massalska T.

Clin Transl Oncol. 2016 Sep;18(9):915-24. doi: 10.1007/s12094-015-1461-1. Epub 2015 Dec 9.

4.

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Dong S, Guo AL, Chen ZH, Wang Z, Zhang XC, Huang Y, Xie Z, Yan HH, Cheng H, Wu YL.

J Hematol Oncol. 2010 Mar 13;3:10. doi: 10.1186/1756-8722-3-10.

5.

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.

Lung Cancer. 2013 Nov;82(2):288-93. doi: 10.1016/j.lungcan.2013.08.018. Epub 2013 Sep 3.

PMID:
24045016
6.

Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.

Niu N, Schaid DJ, Abo RP, Kalari K, Fridley BL, Feng Q, Jenkins G, Batzler A, Brisbin AG, Cunningham JM, Li L, Sun Z, Yang P, Wang L.

BMC Cancer. 2012 Sep 24;12:422. doi: 10.1186/1471-2407-12-422.

7.

Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.

Chen X, Zhang L, Ren S, Li X, Zhou F, Li W, Gao G, He Y, Zhou C.

Med Oncol. 2014 Apr;31(4):865. doi: 10.1007/s12032-014-0865-z. Epub 2014 Feb 18.

PMID:
24535606
8.
9.

Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.

Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, Kucharczyk T, Homa I, Kozioł P, Ciesielka M, Chudziak D, Milanowski J.

Oncol Rep. 2013 Nov;30(5):2385-98. doi: 10.3892/or.2013.2696. Epub 2013 Aug 26.

PMID:
23982437
10.

Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.

Lung Cancer. 2012 Sep;77(3):578-84. doi: 10.1016/j.lungcan.2012.04.016. Epub 2012 May 18.

PMID:
22608006
11.

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R.

Clin Cancer Res. 2008 Mar 15;14(6):1797-803. doi: 10.1158/1078-0432.CCR-07-1364.

12.

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.

Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC.

Clin Cancer Res. 2008 May 15;14(10):3083-8. doi: 10.1158/1078-0432.CCR-07-4591.

13.

RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.

Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, Lv Y, Wei X, Du Y, Jin H, Dong J.

Lung Cancer. 2012 Mar;75(3):374-80. doi: 10.1016/j.lungcan.2011.08.003. Epub 2011 Sep 1.

PMID:
21889227
14.

Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.

Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L.

J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f.

15.

The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.

Xu XL, Zhang YP, Fang Y, Su D, Chen W, Feng JG, Li ZP, Mao WM.

J Cancer Res Ther. 2015 Aug;11 Suppl 1:C49-55. doi: 10.4103/0973-1482.163839.

16.

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.

Soo RA, Wang LZ, Ng SS, Chong PY, Yong WP, Lee SC, Liu JJ, Choo TB, Tham LS, Lee HS, Goh BC, Soong R.

Lung Cancer. 2009 Jan;63(1):121-7. doi: 10.1016/j.lungcan.2008.04.010. Epub 2008 Jun 5.

PMID:
18538445
17.

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, Alberola V, Provencio M, Camps C, De Marinis F, Sanchez JJ, Peñas R.

Semin Oncol. 2003 Aug;30(4 Suppl 10):19-25. Review.

PMID:
12917817
19.
20.

Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.

Lee SY, Kang HG, Yoo SS, Kang YR, Choi YY, Lee WK, Choi JE, Jeon HS, Shin KM, Oh IJ, Kim KS, Lee J, Cha SI, Kim CH, Kim YC, Park JY.

Lung Cancer. 2013 Nov;82(2):330-9. doi: 10.1016/j.lungcan.2013.07.024. Epub 2013 Aug 8.

PMID:
23973201

Supplemental Content

Support Center